Supplementary Table 3. Adverse events in patients with first- and second-line treatment (n=161)

	Frequency (%)	
Adverse event	All grades	Grade ≥ 3
Treatment-related[a]		
Any event	158 (98)	99 (62)
Clinical		
Any event	157 (98)	68 (42)
Fatigue	140 (87)	23 (14)
Nausea and vomiting	105 (65)	4 (2)
Anorexia	101 (63)	10 (6)
Oral mucositis/stomatitis	75 (47)	5 (3)
Constipation	66 (41)	2 (1)
Taste alteration	62 (39)	0
Dry skin	53 (33)	0
Dizziness	49 (30)	0
Neuropathy sensory	46 (29)	0
Dry eyes/watering eyes	44 (27)	0
Diarrhea	41 (25)	4 (2)
Infection with normal neutrophil count	38 (24)	19 (12)
Dysphagia	37 (23)	2 (1)
Rash	30 (19)	0
Weight loss	29 (18)	0
Alopecia	24 (15)	0
Abdominal distension	20 (12)	1 (1)
Pruritus	19 (12)	0
Laboratory		
Any event	154 (96)	68 (42)
Anemia	139 (86)	17 (11)
Decreased white cell count	106 (66)	27 (17)
Decreased neutrophil count	97 (60)	47 (29)
Alanine aminotransferase elevation	80 (50)	2 (1)
Decreased thrombocyte count	78 (48)	17 (11)
Alkaline phosphatase elevation	63 (39)	0
Aspartate aminotransferase elevation	68 (38)	2 (1)
Blood creatinine level elevation	54 (34)	2 (1)

Listed are adverse events that are reported in at least 10% of the patients. [a]Adverse events were scored as treatment-related if investigator defined relatedness as possibly, probably or definitely.